This trial is studying a BRAF inhibitor as a possible treatment for pediatric, adolescent, and young adult patients with cancer.
4 Primary · 22 Secondary · Reporting Duration: Up to 48 months
Experimental Treatment
140 Total Participants · 4 Treatment Groups
Primary Treatment: DAY101 · No Placebo Group · Phase 2
Age 6 - 25 · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: